An FDA advisory panel voted in favor of approving GRAIL's Galleri blood test, which claims to detect more than 50 cancers before symptoms appear, though its accuracy and effect on cancer deaths remain unproven.
FDA panel backs Galleri blood test for detecting over 50 cancers
An FDA advisory panel voted in favor of approving GRAIL's Galleri blood test, which claims to detect more than 50 cancers before symptoms appear, though its accuracy and effect on cancer deaths remain unproven.
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.